LYTIR

Company · ALNY

Alnylam Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as ALNYLAM PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists ALNY on Nasdaq as “Alnylam Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 2 occasions ($543K); insiders sold on 1 occasion ($399K); 1 planned-sale notice; 5 filings by holders of 5% or more; 1 congressional trade disclosure; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $543K in total; Insider sales: $399K in total.Oct: Insider sales $399KNov: Insider purchases $543KDecJanFebMarAprMayJunJulAugSepOctNov$543K$399K
Insider purchases above the line: $543KInsider sales below: $399K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. SUPRAN BRYAN, EVP, CLO and Secretary sold on 1 day latest Oct 2, 2026 sold $399K
  2. Amy W. Schulman bought on 1 day latest Nov 9, 2026 bought $300K
  3. Charles Elliott Sigal bought on 1 day latest Nov 10, 2026 bought $244K
Every trade (3)
  1. BUYCharles Elliott Sigal bought Nov 10, 2026 1,600 shares filing $244K
  2. BUYAmy W. Schulman bought Nov 9, 2026 1,910 shares filing $300K
  3. SELLSUPRAN BRYAN, EVP, CLO and Secretary sold Oct 2, 2026 1,758 shares filing $399K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. SUPRAN BRYAN filed Oct 2, 2026 Officer 1,758 shares planned sale date 10/02/2026 filing $399K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. T. Rowe Price Investment Management, Inc. filed Nov 16, 2026 Schedule 13G passive 10,017,904 shares filing 7.5%
  2. Capital World Investors filed Nov 13, 2026 Schedule 13G/A passive filing 10.4%
  3. Capital Research Global Investors filed Nov 13, 2026 Schedule 13G/A passive filing 8.2%
  4. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 12,675,052 shares filing 9.5%
  5. Vanguard Portfolio Management filed Oct 30, 2026 Schedule 13G passive 6,732,082 shares filing 5.03%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Cory Booker (D-NJ): Sale (Full) Aug 11, 2026 reported Sep 9, 2026 one of 7 trades the member reported that day Senate Stock owner: spouse $1,001 - $15,000

Executive branch · OGE Form 278-T

Reported by the President

8 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports

  1. Purchase: ALNYLAM PHARMACEUTICALS Aug 28, 2026 reported Sep 17, 2026 President Donald J. Trump Periodic Transaction Report 09.17.26 $1,001 – $15,000
  2. Purchase: ALNYLAM PHARMACEUTICALS Aug 10, 2026 reported Sep 17, 2026 President Donald J. Trump Periodic Transaction Report 09.17.26 $1,001 – $15,000
  3. Sale: ALNYLAM PHARMACEUTICALS INC Jun 16, 2026 reported Aug 12, 2026 President Donald J. Trump Periodic Transaction Report 08.12.26 $15,001 – $50,000
  4. Sale: ALNYLAM PHARMACEUTICALS May 18, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (2) $1,001 – $15,000
  5. Purchase: ALNYLAM PHARMACEUTICALS INC Apr 15, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (1) $1,001 – $15,000
  6. Purchase: ALNYLAM PHARMACEUTICALS INC Apr 7, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (1) $1,001 – $15,000
  7. Purchase: ALNYLAM PHARMACEUTICALS Mar 23, 2026 reported May 8, 2026 President Donald J. Trump Periodic Transaction Report 05.08.26 (1) $1,001 – $15,000
  8. Purchase: ALNYLAM PHARMACEUTICALS INC Jan 23, 2026 reported May 8, 2026 President Donald J. Trump Periodic Transaction Report 05.08.26 (1) $1,001 – $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Departure or appointment of directors or officers; Other events filing Nov 5, 2026
  2. Results of operations and financial condition filing Oct 29, 2026

Lobbying · Senate LDA reports

Lobbying filed

6 quarterly lobbying reports for 2026 naming Alnylam Pharmaceuticals, Inc. as the client: 1 filed by the company itself, 5 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. The company itself Q1 2026 filing $430K
  2. TODD STRATEGY GROUP Q1 2026 filing $60K
  3. SPLITOAK STRATEGIES LLC Q1 2026 filing $60K
  4. TIBER CREEK GROUP Q1 2026 filing $60K
  5. CAPITOL COUNSEL LLC Q1 2026 filing $60K
  6. LMH STRATEGIC SOLUTIONS Q1 2026 filing $50K

Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.